BRPI0414714A - polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição - Google Patents
polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composiçãoInfo
- Publication number
- BRPI0414714A BRPI0414714A BRPI0414714-6A BRPI0414714A BRPI0414714A BR PI0414714 A BRPI0414714 A BR PI0414714A BR PI0414714 A BRPI0414714 A BR PI0414714A BR PI0414714 A BRPI0414714 A BR PI0414714A
- Authority
- BR
- Brazil
- Prior art keywords
- nemo oligomerization
- methods
- capab
- modulate
- inhibiting
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 238000006384 oligomerization reaction Methods 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000019491 signal transduction Effects 0.000 title abstract 2
- -1 host cell Proteins 0.000 title 1
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000007503 antigenic stimulation Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000025915 regulation of apoptotic process Effects 0.000 abstract 1
- 230000025053 regulation of cell proliferation Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"POLINUCLEOTìDEO PURIFICADO, VETOR, CéLULA HOSPEDEIRA, CONSTRUTO DE FUSãO DE POLIPEPTìDEO, MéTODOS DE INIBIR A ROTA DE SINALIZAçãO DE NF-CAPAB, DE INTERROMPER A OLIGOMERIZAçãO DE NEMO, E DE IDENTIFICAR POLIPEPTìDEOS QUE MODULAM A OLIGOMERIZAçãO DE NEMO, E, USO DE UMA QUANTIDADE EFICAZ DE UMA COMPOSIçãO". A presente invenção refere-se aos polipeptídeos que inibem a rota de sinalização de NF-<sym>B e os polinucleotídeos codificadores dos mesmos. A presente invenção adicionalmente proporciona métodos para a modulação e/ou o tratamento de respostas inflamatórias, oncogênese, infecção viral; a regulação de proliferação e apoptose celulares; e regulação de linfócitos B ou T em estimulação antigênica, pela administração de polipeptídeos da presente invenção a um indivíduo em necessidade da mesma. Finalmente, a presente invenção proporciona um método de identificar os polipeptídeos que modulam a oligomerização de NEMO.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50516103P | 2003-09-24 | 2003-09-24 | |
| US53041803P | 2003-12-18 | 2003-12-18 | |
| PCT/IB2004/003352 WO2005027959A1 (en) | 2003-09-24 | 2004-09-24 | Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414714A true BRPI0414714A (pt) | 2006-11-21 |
Family
ID=34381127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414714-6A BRPI0414714A (pt) | 2003-09-24 | 2004-09-24 | polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7390872B2 (pt) |
| EP (1) | EP1677815B8 (pt) |
| JP (1) | JP5027508B2 (pt) |
| KR (1) | KR20060090714A (pt) |
| CN (1) | CN1886148B (pt) |
| AU (1) | AU2004273686B2 (pt) |
| BR (1) | BRPI0414714A (pt) |
| CA (1) | CA2540103C (pt) |
| WO (1) | WO2005027959A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| BRPI0414714A (pt) * | 2003-09-24 | 2006-11-21 | Pasteur Institut | polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição |
| US20060068032A1 (en) * | 2004-09-24 | 2006-03-30 | Sunny Biodiscovery, Inc. | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof |
| WO2008148016A1 (en) * | 2007-05-25 | 2008-12-04 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Inhibiting the signs of aging by inhibiting nf-kappa b activation |
| EP2006686A1 (en) * | 2007-06-22 | 2008-12-24 | Institut Pasteur | Method for screening for selective modulator of the NF-kB pathway activation |
| FR2927080A1 (fr) * | 2008-02-05 | 2009-08-07 | Servier Lab | Structure cristalline du domaine cc2-lz de nemo |
| MX361242B (es) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
| US20130210875A1 (en) * | 2012-02-10 | 2013-08-15 | Macau University Of Science And Technology | Novel binding site of IKK-beta |
| EP3184541A1 (en) * | 2015-12-23 | 2017-06-28 | Institut Pasteur | Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs |
| AU2017340387A1 (en) | 2016-10-04 | 2019-05-02 | University Of Florida Research Foundation, Inc. | Targeted effector proteins and uses thereof |
| US11407797B2 (en) | 2017-10-11 | 2022-08-09 | University Of Florida Research Foundation, Incorporated | Modified gal-1 proteins and uses thereof |
| US12577282B2 (en) | 2019-02-28 | 2026-03-17 | University Of Florida Research Foundation, Incorporated | Galectin-1/ galectin-3 chimeras and multivalent proteins |
| CN111606976A (zh) * | 2020-05-26 | 2020-09-01 | 中国人民解放军军事科学院军事医学研究院 | 一种小肽及其在抑制阿片成瘾性和耐受性上的应用 |
| CN114539426B (zh) * | 2022-03-02 | 2023-07-07 | 山东仙普爱瑞科技股份有限公司 | 一种含干扰素α的融合蛋白、表达该融合蛋白的重组菌株及其制备方法 |
| WO2024251897A1 (en) | 2023-06-08 | 2024-12-12 | Centre National De La Recherche Scientifique | PEPTIDE AND POLYPEPTIDE INHIBITING THE NF-kB SIGNALING PATHWAY |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126024A0 (en) * | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
| ES2251831T3 (es) | 1998-05-06 | 2006-05-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Inhibidores de la activacion de nf-kb. |
| US6680366B1 (en) * | 1999-02-22 | 2004-01-20 | Institut Pasteur | Nucleotide sequence encoding a modulator of NF-κB |
| EP1157126A4 (en) * | 1999-02-24 | 2005-03-02 | Gen Hospital Corp | METHOD FOR CLONING INTERMEDIATE SIGNAL TRANSDUCTION PRODUCTS |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20060040319A1 (en) * | 2000-01-14 | 2006-02-23 | Tom Muir | Multiple sensor-containing active modified polypeptides, preparation and uses thereof |
| WO2002057413A2 (en) * | 2001-01-18 | 2002-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| US20030165985A1 (en) * | 2001-05-08 | 2003-09-04 | Derry Jonathan M.J. | Methods for identifying compounds that antagonize cd40 signaling |
| ATE334696T1 (de) | 2001-06-22 | 2006-08-15 | Vlaams Interuniv Inst Biotech | Abin zum schutz gegen hepatitis |
| BRPI0414714A (pt) * | 2003-09-24 | 2006-11-21 | Pasteur Institut | polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição |
| US7413863B2 (en) * | 2006-06-08 | 2008-08-19 | Institut Pasteur | Identification of substances that inhibit NEMO oligomerization |
-
2004
- 2004-09-24 BR BRPI0414714-6A patent/BRPI0414714A/pt not_active Application Discontinuation
- 2004-09-24 WO PCT/IB2004/003352 patent/WO2005027959A1/en not_active Ceased
- 2004-09-24 EP EP04769635.6A patent/EP1677815B8/en not_active Expired - Lifetime
- 2004-09-24 AU AU2004273686A patent/AU2004273686B2/en not_active Ceased
- 2004-09-24 JP JP2006527513A patent/JP5027508B2/ja not_active Expired - Fee Related
- 2004-09-24 KR KR1020067007920A patent/KR20060090714A/ko not_active Ceased
- 2004-09-24 US US10/948,649 patent/US7390872B2/en not_active Expired - Fee Related
- 2004-09-24 CA CA2540103A patent/CA2540103C/en not_active Expired - Fee Related
- 2004-09-24 US US10/573,161 patent/US7700553B2/en not_active Expired - Fee Related
- 2004-09-24 CN CN2004800346979A patent/CN1886148B/zh not_active Expired - Fee Related
-
2008
- 2008-04-24 US US12/108,668 patent/US8790883B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080207517A1 (en) | 2008-08-28 |
| AU2004273686A1 (en) | 2005-03-31 |
| CN1886148B (zh) | 2013-01-02 |
| JP5027508B2 (ja) | 2012-09-19 |
| WO2005027959A1 (en) | 2005-03-31 |
| AU2004273686B2 (en) | 2011-03-03 |
| CA2540103A1 (en) | 2005-03-31 |
| JP2007506422A (ja) | 2007-03-22 |
| EP1677815B8 (en) | 2017-08-30 |
| KR20060090714A (ko) | 2006-08-14 |
| US20050220792A1 (en) | 2005-10-06 |
| US8790883B2 (en) | 2014-07-29 |
| CN1886148A (zh) | 2006-12-27 |
| US7390872B2 (en) | 2008-06-24 |
| US7700553B2 (en) | 2010-04-20 |
| US20080242601A1 (en) | 2008-10-02 |
| EP1677815A1 (en) | 2006-07-12 |
| CA2540103C (en) | 2017-11-07 |
| EP1677815B1 (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414714A (pt) | polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição | |
| FI953812A0 (fi) | Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja | |
| BR9711550A (pt) | Sulfonamidas e seus derivados que modulam a atividade da endotelina. | |
| ATE309347T1 (de) | Protocadherin-proteine und verwendungen davon | |
| BR9814956A (pt) | Inibidores de benzotiazol da tirosina cinase de proteìna | |
| FI963630A0 (fi) | IFN-beta:n uusia muteiineja | |
| BR9305617A (pt) | Uso de isolados de bacillus thuringiensis para controlar pragas na familia dos afidideos | |
| DE3671640D1 (de) | Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben. | |
| BR0303482A (pt) | Aparelho para uso no controle e/ou nos testes de um sistema de produção de hidrocarboneto | |
| DK0631502T3 (da) | Lymfocytaktivitetsregulering ved hjælp af HLA-peptider | |
| DK540986A (da) | 2-substitueret-(2-substitueret amino)-n-arylalkyl-3-(indol-3-yl)propanamider, fremgangsmaade til deres fremstilling samt deres anvendelse | |
| BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
| BRPI0507776A (pt) | métodos de modular a atividade de citocina; reagentes relacionados | |
| DE69909293D1 (de) | Flüssigkristalline verbindungen | |
| BR112022005159A2 (pt) | Proteína de fusão fc, composição farmacêutica, método de prevenção ou tratamento de um câncer e método para induzir imunidade ou restaurar a capacidade de resposta à imunoterapia | |
| NO910561D0 (no) | Formmasse av elastomere polyolefingummier, polyetylener og/eller etylenkopolymerer og tilsatsstoffer, samt deres anvendelse for elastiske tetningsbaner. | |
| BR9914892A (pt) | Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor | |
| ATE302215T1 (de) | Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten | |
| BR0207253A (pt) | Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado | |
| BR112022000847A2 (pt) | Método para inativação viral | |
| BR9807271A (pt) | Tamoxifeno como terapia para reduzir diarréia induzida por cloridrato de irinotecano | |
| BRPI0408778A (pt) | proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas | |
| DE69619530D1 (de) | Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität | |
| WO1999047709A3 (en) | Methods for identifying anti-cancer agents | |
| BRPI0417250A (pt) | peptìdios e polinucleotìdio isolados e purificados, anticorpos, vetor, célula hospedeira, métodos de inibição de agregação plaquetária, da ligação do fibrinogênio a plaquetas, de uso de polinucleotìdio para a produção de proteìna e de tratamento de pessoa e composições farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal: dismissal of application maintained |